Processa Pharmaceuticals price to book ratio PCSA

Market value divided by the book value of the company's net assets, since 2018.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 2.6×; Aug 2026
8-year median: 2.5×
8-year range: 0.4× to 25.1×
Peer median: 1.0×

Processa Pharmaceuticals' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Aug 2026, at 2.6×.

On the days it had one over the last 8 years, its median was 2.5×, from 0.4× in Mar 2024 to 25.1× in Mar 2021.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.6×	0.8×	3.2×
2025	1.5×	0.4×	3.2×
2024	0.8×	0.4×	1.6×
2023	1.1×	0.4×	2.6×
2022	1.0×	1.0×	2.7×
2021	2.8×	2.7×	25.1×
2020	12.6×	3.3×	14.7×
2019	8.1×	6.5×	13.4×
2018	12.0×	6.3×	23.2×

Against its peers

Companies in Healthcare nearest Processa Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
PCSAProcessa Pharmaceuticals	n/m
OXBROXBRIDGE RE HOLDINGS	1.2×
EDUCEducational Development	0.2×
GTIMGood Times Restaurants	0.4×
MDRRMedalist Diversified	0.6×
BCGBinah Capital	0.9×
VIPVulcan Infrastructure & Power	n/m
MXCMexco Energy	1.0×
CKXCKX Lands	1.0×
MSGMMotorsport Games	5.8×
ATCHAtlasClear	1.1×
Peer median	1.0×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Processa Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.